In January 2021

lixue123

In January 2021, Pfizer announced that its Oxoidplatform technology successfully passed the Emergency Use Authorization (EMA) review of the U.S. Food and Drug Administration (FDA) and planned to launch a new crown vaccine at the end of 2021. In May 2021, the inactivated new coronavirus vaccine (BNT162b2) jointly developed by Pfizer and German BioNTech was successful in the Phase 3 trial and became the world's first new crown vaccine to obtain conditional marketing authorization from the FDA.